Design of second generation therapeutic recombinant bone morphogenetic proteins

Cytokine and Growth Factor Reviews

Volumn 20, Issue 5-6, 2009, Pages 501-507

  Alaoui Ismaili, Moulay Hicham ^a   Falb, Dean ^a  

^a Stryker Orthopaedics   (United States)

Author keywords

Bone morphogenetic protein; Engineering; Improved activity; Potency; Safety

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR; GROWTH DIFFERENTIATION FACTOR 5; NOGGIN; OSTEOGENIC PROTEIN 1; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1;

BINDING AFFINITY; BONE REGENERATION; CELL SURFACE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG STABILITY; EXTRACELLULAR SPACE; FRACTURE NONUNION; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SPINE FUSION;

BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MUTANT PROTEINS; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 70849086706     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2009.10.001     Document Type: Review

References (64)

1. Urist M.R. Bone: formation by autoinduction. Science 150 (1965) 893-899
2. Urist M.R., Iwata H., Ceccotti P.L., Dorfman R.L., Boyd S.D., McDowell R.M., et al. Bone morphogenesis in implants of insoluble bone gelatin. Proc Natl Acad Sci USA 70 (1973) 3511-3515
3. Wang E.A., Rosen V., Cordes P., Hewick R.M., Kriz M.J., Luxenberg D.P., et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci USA 85 (1988) 9484-9488
4. Celeste A.J., Iannazzi J.A., Taylor R.C., Hewick R.M., Rosen V., Wang E.A., et al. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87 (1990) 9843-9847
5. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 242 (1988) 1528-1534
6. Ozkaynak E., Rueger D.C., Drier E.A., Corbett C., Ridge R.J., Sampath T.K., et al. OP-1 cDNA encodes an osteogenic protein in the TGF-beta family. EMBO J 9 (1990) 2085-2093
7. Allendorph G.P., Vale W.W., and Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 103 (2006) 7643-7648
8. ten Dijke P. Bone morphogenetic protein signal transduction in bone. Curr Med Res Opin 22 Suppl. 1 (2006) S7-11
9. Sebald W., Nickel J., Zhang J.L., and Mueller T.D. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 385 (2004) 697-710
10. Gazzerro E., and Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7 (2006) 51-65
11. Tsialogiannis E., Polyzois I., Oak Tang Q., Pavlou G., Tsiridis E., Heliotis M., et al. Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets 13 (2009) 123-137
12. Gautschi O.P., Frey S.P., and Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 77 (2007) 626-631
13. Perri B., Cooper M., Lauryssen C., and Anand N. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J 7 (2007) 235-239
14. Zeisberg M., and Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 82 (2004) 175-181
15. Zeisberg M., Shah A.A., and Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280 (2005) 8094-8100
16. Scheufler C., Sebald W., and Hulsmeyer M. Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J Mol Biol 287 (1999) 103-115
17. Allendorph G.P., Isaacs M.J., Kawakami Y., Belmonte J.C., and Choe S. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 46 (2007) 12238-12247
18. Saremba S., Nickel J., Seher A., Kotzsch A., Sebald W., and Mueller T.D. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J 275 (2008) 172-183
19. Griffith D.L., Keck P.C., Sampath T.K., Rueger D.C., and Carlson W.D. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc Natl Acad Sci USA 93 (1996) 878-883
20. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 280 (2005) 25111-25118
21. Nickel J., Kotzsch A., Sebald W., and Mueller T.D. A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 349 (2005) 933-947
22. Keller S., Nickel J., Zhang J.L., Sebald W., and Mueller T.D. Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 11 (2004) 481-488
23. Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W., et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 11 (2003) 605-617
24. Weber D., Kotzsch A., Nickel J., Harth S., Seher A., Mueller U., et al. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol 7 (2007) 6
25. Lavery K.S., Swain P.M., Falb D., and Alaoui-Ismaili M.H. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow derived mesenchymal stem cells. J Biol Chem 283 (2008) 20948-20958
26. Xia Y., Yu P.B., Sidis Y., Beppu H., Bloch K.D., Schneyer A.L., et al. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem 282 (2007) 18129-18140
27. Kirsch T., Nickel J., and Sebald W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 19 (2000) 3314-3324
28. Chang H., Brown C.W., and Matzuk M.M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 23 (2002) 787-823
29. Yi S.E., Daluiski A., Pederson R., Rosen V., and Lyons K.M. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 127 (2000) 621-630
30. Yanagita M. BMP modulators regulate the function of BMP during body patterning and disease progression. Biofactors 35 (2009) 113-119
31. Gazzerro E., Gangji V., and Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 102 (1998) 2106-2114
32. Lavery K., Hawley S., Swain P., Rooney R., Falb D., and Alaoui-Ismaili M.H. New insights into BMP-7 mediated osteoblastic differentiation of primary human mesenchymal stem cells. Bone 45 (2009) 27-41
33. Pereira R.C., Economides A.N., and Canalis E. Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts. Endocrinology 141 (2000) 4558-4563
34. Rosen V. BMP and BMP inhibitors in bone. Ann NY Acad Sci 1068 (2006) 19-25
35. Dimitriou R., Tsiridis E., Carr I., Simpson H., and Giannoudis P.V. The role of inhibitory molecules in fracture healing. Injury 37 Suppl. 1 (2006) S20-29
36. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420 (2002) 636-642
37. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., et al. Structural basis of BMP signaling inhibition by Noggin, a novel twelve-membered cystine knot protein. J Bone Joint Surg Am 85A Suppl. 3 (2003) 52-58
38. Zimmerman L.B., De Jesus-Escobar J.M., and Harland R.M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86 (1996) 599-606
39. Haudenschild D.R., Palmer S.M., Moseley T.A., You Z., and Reddi A.H. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64 (2004) 8276-8284
40. Dixon M.E., Armstrong P., Stevens D.B., and Bamshad M. Identical mutations in NOG can cause either tarsal/carpal coalition syndrome or proximal symphalangism. Genet Med 3 (2001) 349-353
41. Gong Y., Krakow D., Marcelino J., Wilkin D., Chitayat D., Babul-Hirji R., et al. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat Genet 21 (1999) 302-304
42. Marcelino J., Sciortino C.M., Romero M.F., Ulatowski L.M., Ballock R.T., Economides A.N., et al. Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. Proc Natl Acad Sci USA 98 (2001) 11353-11358
43. Takahashi T., Takahashi I., Komatsu M., Sawaishi Y., Higashi K., Nishimura G., et al. Mutations of the NOG gene in individuals with proximal symphalangism and multiple synostosis syndrome. Clin Genet 60 (2001) 447-451
44. Devlin R.D., Du Z., Pereira R.C., Kimble R.B., Economides A.N., Jorgetti V., et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144 (2003) 1972-1978
45. Wan D.C., Pomerantz J.H., Brunet L.J., Kim J.B., Chou Y.F., Wu B.M., et al. Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 282 (2007) 26450-26459
46. Gazzerro E., Pereira R.C., Jorgetti V., Olson S., Economides A.N., and Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 146 (2005) 655-665
47. Kwong F.N., Richardson S.M., and Evans C.H. Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells. Arthritis Res Ther 10 (2008) R65
48. Zhang J.L., Qiu L.Y., Kotzsch A., Weidauer S., Patterson L., Hammerschmidt M., et al. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell 14 (2008) 739-750
49. Jones W.K., Richmond E.A., White K., Sasak H., Kusmik W., Smart J., et al. Osteogenic protein-1 (OP-1) expression and processing in Chinese hamster ovary cells: isolation of a soluble complex containing the mature and pro-domains of OP-1. Growth Factors 11 (1994) 215-225
50. Israel D.I., Nove J., Kerns K.M., Moutsatsos I.K., and Kaufman R.J. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 7 (1992) 139-150
51. Swencki-Underwood B., Mills J.K., Vennarini J., Boakye K., Luo J., Pomerantz S., et al. Expression and characterization of a human BMP-7 variant with improved biochemical properties. Protein Expr Purif 57 (2008) 312-319
52. Thomas J.T., Prakash D., Weih K., and Moos Jr. M. CDMP1/GDF5 has specific processing requirements that restrict its action to joint surfaces. J Biol Chem 281 (2006) 26725-26733
53. Constam D.B., and Robertson E.J. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol 144 (1999) 139-149
54. Hwang C.J., Vaccaro A.R., Lawrence J.P., Hong J., Schellekens H., Alaoui-Ismaili M.H., et al. Immunogenicity of bone morphogenetic proteins. J Neurosurg Spine 10 (2009) 443-451
55. De Groot A.S., and Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol 28 (2007) 482-490
56. Onda M. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 10 (2009) 131-139
57. Perry L.C., Jones T.D., and Baker M.P. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 9 (2008) 385-396
58. Stas P., and Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 12 (2009) 169-173
59. Aono A., Hazama M., Notoya K., Taketomi S., Yamasaki H., Tsukuda R., et al. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210 (1995) 670-677
60. Israel D.I., Nove J., Kerns K.M., Kaufman R.J., Rosen V., Cox K.A., et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13 (1996) 291-300
61. Zhu W., Rawlins B.A., Boachie-Adjei O., Myers E.R., Arimizu J., Choi E., et al. Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 19 (2004) 2021-2032
62. Koh J.T., Zhao Z., Wang Z., Lewis I.S., Krebsbach P.H., and Franceschi R.T. Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration. J Dent Res 87 (2008) 845-849
63. Zhu W., Kim J., Cheng C., Rawlins B.A., Boachie-Adjei O., Crystal R.G., et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39 (2006) 61-71
64. Seemann P., Schwappacher R., Kjaer K.W., Krakow D., Lehmann K., Dawson K., et al. Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. J Clin Invest 115 9 (2005) 2373-2381